The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse)

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 42; no. 2; p. 192
• Main Authors: Bloch, Mark T, Smith, Don E, Quan, Dick, Kaldor, John M, Zaunders, John J, Petoumenos, Kathy, Irvine, Kathy, Law, Matthew, Grey, Pat, Finlayson, Robert J, McFarlane, Robert, Kelleher, Anthony D, Carr, Andrew, Cooper, David A
• Format: Journal Article
• Language: English
• Published: United States 01.06.2006
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - adverse effects; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; HIV - drug effects; HIV Infections - drug therapy; Homosexuality; Humans; Hydroxyurea - administration & dosage; Hydroxyurea - adverse effects; Hydroxyurea - pharmacology; Hydroxyurea - therapeutic use; Male; RNA, Viral - blood; Treatment Outcome; Viral Load

Structured treatment interruptions (STIs) have been postulated to improve virologic control in primary HIV infection (PHI) by stimulating HIV-specific T-lymphocyte immunity. The addition of hydroxyurea (HU) may reduce viral production from activated CD4 cells. Patients with PHI received a standardiz...